Abstract
The novel Coronavirus SARS-CoV-2 (COVID-19) has induced a world-wide pandemic and subsequent non-pharmaceutical interventions (NPI) in order to control the spreading of the virus. NPIs are considered to be critical in order to at least delay the peak number of infected individuals and to prevent the health care system becoming overwhelmed by the number of patients to treat in hospitals or in intensive care units (ICUs). However, there is also increasing concern that the NPIs in place would increase mortality because of other diseases, increase the frequency of suicide and increase the risk of an economic recession with unforeseeable implications. It is therefore instrumental to evaluate the necessity of NPIs and to monitor the progress of containment of virus spreading. We used a data-driven estimation of the evolution of the reproduction number for viral spreading in Germany as well as in all its federal states. Based on an extended infection-epidemic model, parameterized with data from the Robert Koch Institute and, alternatively, with parameters stemming from a fit to the initial phase of COVID-19 spreading in different regions of Italy, we found that the reproduction number was decreased to a range below 1 in all federal states. The development in Germany suggests that NPIs can be partially released based on an established new culture of social distancing, face masks and mutual care within the population. However, any release of measures delays reaching low incidence numbers. The strategy to reduce daily new cases to a sufficiently low level to be controlled by contact tracing and testing turned out to work in Germany. This requires a responsible behaviour of the population, optimised contact tracing techniques and extended testing capacities in contact clusters.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 101003480 and the Initiative and Networking Fund of the Helmholtz Association.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The full data set associated with the research of the paper is made available online. See URL below.
